Soufia M, Aoun J, Gorsane M-A, Krebs M-O
Université Saint-Joseph, Beyrouth, Liban.
Encephale. 2010 Dec;36(6):513-6. doi: 10.1016/j.encep.2010.02.003. Epub 2010 Apr 3.
A review of the consequences of maternal depression on fetal and infant development and the risk and benefits of SSRI use.
We have reviewed the literature published on PubMed between January 1980 and February 2009 using the following keywords: SSRI, depression, pregnancy, abnormality, teratogenic effect.
Pregnancies complicated by the onset or recurrence of a major depressive disorder constitute a complex medical situation. The management of such situations is based on the principle of avoiding, as far as possible, the exposure of the developing foetus to both the maternal illness and the potential teratogenic effects of psychotropic drugs. Epidemiological studies show that maternal depression is a very frequent disease: 10 to 16% of pregnant women fulfill major depressive disorder diagnostic criteria and 15% suffer from postpartum depression. The consequences of such exposure on fetal and infant development are so harmful that a pharmacological treatment is highly recommended. Nowadays, the information available on the safety of SSRI use in pregnancy is abundant and these molecules are probably the most studied drugs in pregnant women. Their beneficial effects largely prevail over their potential fetal/neonatal risks and it is unlikely that any marked teratogenic effect occurs, with the possible exception of an increased risk for cardiovascular defects after maternal use of paroxetine. However, transient neonatal symptoms are common after SSRI use in late pregnancy. These include transient autonomic, gastrointestinal, somatic, and clinical respiratory manifestations in the immediate neonatal period.
Treatment of maternal depression during pregnancy and immediate neonatal period is uniformly recommended despite the potential side effects on the fetus and newborn. With a possible exception for paroxetine, maternal treatment with SSRIs during pregnancy is not associated with significantly increased risks of congenital defects.
综述母亲抑郁对胎儿及婴儿发育的影响以及使用选择性5-羟色胺再摄取抑制剂(SSRI)的风险与益处。
我们使用以下关键词检索了1980年1月至2009年2月发表于PubMed上的文献:SSRI、抑郁、妊娠、异常、致畸作用。
合并重度抑郁症发作或复发的妊娠构成一种复杂的医疗情况。此类情况的处理基于尽可能避免发育中的胎儿暴露于母亲疾病及精神药物潜在致畸作用的原则。流行病学研究表明,母亲抑郁是一种非常常见的疾病:10%至16%的孕妇符合重度抑郁症诊断标准,15%患有产后抑郁症。这种暴露对胎儿及婴儿发育的影响非常有害,因此强烈建议进行药物治疗。如今,关于妊娠期间使用SSRI安全性的可用信息很多,这些药物可能是孕妇中研究最多的药物。它们的有益作用在很大程度上超过其潜在的胎儿/新生儿风险,除母亲使用帕罗西汀后心血管缺陷风险可能增加外,不太可能出现明显的致畸作用。然而,妊娠晚期使用SSRI后,短暂的新生儿症状很常见。这些包括新生儿期即刻出现的短暂自主神经、胃肠道、躯体及临床呼吸表现。
尽管对胎儿和新生儿可能有副作用,但一致推荐在孕期及新生儿期即刻治疗母亲抑郁。除帕罗西汀可能为例外,孕期母亲使用SSRI与先天性缺陷风险显著增加无关。